Shared immune-inflammatory gene networks and drug prediction in polycystic ovary syndrome and type 2 diabetes mellitus: a bioinformatics and experimental validation study - Takeaways - MDSpire

Shared immune-inflammatory gene networks and drug prediction in polycystic ovary syndrome and type 2 diabetes mellitus: a bioinformatics and experimental validation study

  • By

  • Xuemeng Liu

  • Yanlei Wang

  • Qiuhan Bi

  • Ying Zhang

  • Shumin Wang

  • Pan Yang

  • Jie Pei

  • Weixi Zhu

  • Yijing Chen

  • Zhiguo Zhang

  • Beili Chen

  • Qiu Zhang

  • Yi Zhang

  • Tian Jiang

  • April 16, 2026

  • 0 min

Share

  • 1

    The study identified 239 common differentially expressed genes (DEGs) linked to immune regulation and inflammation in PCOS and T2DM.

  • 2

    Nine hub genes, including ITGAM, ITGB2, and SPI1, were identified as key regulators in the comorbidity of PCOS and T2DM.

  • 3

    Gene regulatory networks involving transcription factors and miRNAs were constructed to elucidate shared molecular mechanisms.

  • 4

    Potential therapeutic drugs targeting hub genes were predicted, including maraviroc and cenicriviroc, which may offer novel treatment strategies.

  • 5

    Further validation through clinical and experimental studies is necessary to confirm the findings and therapeutic implications.

Original Source(s)

Shared immune-inflammatory gene networks and drug prediction in polycystic ovary syndrome and type 2 diabetes mellitus: a bioinformatics and experimental validation study

  • by Xuemeng Liu, Yanlei Wang, Qiuhan Bi, Ying Zhang, Shumin Wang, Pan Yang, Jie Pei, Weixi Zhu, Yijing Chen, Zhiguo Zhang, Beili Chen, Qiu Zhang, Yi Zhang, Tian Jiang

  • April 16, 2026

Related Content

Editorial: Advancing reproductive outcomes: integrating molecular, metabolic, and endocrine insights into oocyte maturation

Integrating evidence-based lifestyle and adjunct therapies for long-term management of polycystic ovary syndrome: mechanistic insights and clinical implications

Keeping an Eye on Diabetes

Progress, pitfalls and the future of the UK’s Diabetic Eye Screening Program